InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.11
(
-0.01%
)
US TECH 100
18,381.60
(
0.35%
)
Dow Jones
38,833.21
(
-0.61%
)
Brent Oil
83.92
(
1.30%
)
Bitcoin
67,617.07
(
-2.56%
)
Post# of 251948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

semi_infinite

Send PM Follow Ignore
Followers 14
Posts 3812
Boards Moderated 1
Alias Born 07/07/2002

semi_infinite

Re: semi_infinite post# 237697

Friday, 04/01/2022 12:09:50 PM

Friday, April 01, 2022 12:09:50 PM

Post# of 251948
AFMD - AFM13-cbNK (anti cd30 NK) one year later. ER yesterday and Innate Cell Summit (san diego) today revealed 100% ORR continues at rp2d. Plus deepening of response with 2nd cycle. MDACC paper accepted for plenary session at next week's AACR annual mtg. Only non big pharma bio chosen. Data cutoff for that was October 2021. Shall add interesting color to response and duration. Company discussion with payers suggest car-t level pricing if fda cleared.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up